<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-43508" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>QT Prolonging Drugs</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tivakaran</surname>
            <given-names>Vijai S.</given-names>
          </name>
          <aff>Kettering Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vijai Tivakaran declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-43508.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The heart has an electrical system that allows it to contract in a rhythm. A vital aspect of this electrical system is depolarization and repolarization. The focus of this activity is on the QT interval. It is measured from the Q wave until the T wave, and the QT interval clinically represents the repolarization of the ventricles. Many commonly used medications exhibit QT-prolonging effects. However, the degree of QT prolongation is not severe enough to warrant caution in healthy patients. This activity outlines the mechanism of action, significant adverse effects, contraindications, monitoring, and toxicity of QT-prolonging medications, so the interprofessional team can direct patient therapy in treating conditions where patients are using these agents, in particular when they have multiple such agents.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the possible mechanisms by which drugs might prolong the QT interval.</p></list-item><list-item><p>Summarize the at-risk patient populations for QT-prolonging medications.</p></list-item><list-item><p>Review the necessary monitoring when patients are using medications that can cause QT prolongation.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance and monitor the delivery of care for patients who are using medications that can prolong the QT interval.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43508">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-43508.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The heart has an electrical&#x000a0;system that allows it to contract in a rhythm. A vital aspect of this electrical system is depolarization and repolarization. The electrical activity is conducted through the sinoatrial (SA) node and atrioventricular (AV) node and into the ventricles. This electrical activity is clearly&#x000a0;outlined on an electrocardiogram (ECG) with P waves, the QRS complex, and T waves. The P wave represents the electrical activity of the atrium. The QRS complex shows the depolarization of the ventricles. Lastly, the T wave shows the repolarization of the ventricles.<xref ref-type="bibr" rid="article-43508.r1">[1]</xref><xref ref-type="bibr" rid="article-43508.r2">[2]</xref></p>
        <p>The focus of this article is on the QT interval. It is measured&#x000a0;from the Q wave until the T wave, and the QT interval clinically represents the repolarization of the ventricles. When measured on an ECG, the QT interval lengthens when the heart is beating slower and shortens when the heart is beating faster.&#x000a0;That is why an adjusted version of the QT interval is used:&#x000a0;QTc. This allows for an accurate QT interval at lower and higher heart rates. There are different formulas used to obtain&#x000a0;the QTc interval.<xref ref-type="bibr" rid="article-43508.r3">[3]</xref><xref ref-type="bibr" rid="article-43508.r4">[4]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Bazett</p>
          </list-item>
          <list-item>
            <p>Fridericia</p>
          </list-item>
          <list-item>
            <p>Framingham</p>
          </list-item>
        </list>
        <p>Bazett's is the most commonly used formula and is done by dividing the QT interval by the square root of the R-R interval.<xref ref-type="bibr" rid="article-43508.r5">[5]</xref> Fridericia is a similar formula, except it uses the cube root of the R-R interval.<xref ref-type="bibr" rid="article-43508.r6">[6]</xref><xref ref-type="bibr" rid="article-43508.r7">[7]</xref> Framingham is a more complex formula, but the literature has shown it may be the most superior formula. Bazett's is automatically calculated on most ECG machines, and its limitations are underestimation and overestimation of the QTc in the cases of bradycardia and tachycardia, respectively. Its accuracy is limited mainly to heart rates of 60 to 100 beats per minute, and clinicians must factor in the heart rate when assessing the QTc.<xref ref-type="bibr" rid="article-43508.r8">[8]</xref>&#x000a0;Optimal accuracy is achieved in the 60&#x000a0;to 80 heart rate range.</p>
        <p>A normal QTc in a male is 440 ms or less, and in a female, it is 460 ms or less. Those with prolonged QT are at risk for one of the potentially deadly arrhythmias known as torsades de pointes. It is a form of polymorphic ventricular tachycardia, an unstable cardiac rhythm. This rhythm may cease on its own and go into sinus rhythm or degenerate into ventricular fibrillation. It is important to distinguish torsades de pointes from other forms of polymorphic ventricular tachycardia. For an arrhythmia to be classified as torsades de pointes, it must also occur in the setting of QT prolongation. Other forms of polymorphic ventricular tachycardia can occur with a normal QT interval and usually occur due to ischemia.</p>
        <p>The most common symptom of Torsades de Pointes is syncope. If hemodynamically unstable, patients with torsades are administered a 2&#x000a0;to 4 g bolus of magnesium sulfate and must undergo cardioversion. Isoproterenol can also&#x000a0;be used to increase the heart rate, thereby&#x000a0;decreasing the absolute QT interval. However, this medication has limited availability in many settings. Other second-line options can include lidocaine. Amiodarone, while used for ventricular tachycardia, should generally not be used as it has some QT-prolonging properties. Phenytoin has also been identified as a potential third-line treatment option.</p>
        <p>It&#x000a0;is&#x000a0;generally&#x000a0;accepted that QT prolongation past 500 ms carries an increased risk of torsades de pointes. The degree of QT prolongation is correlated to the level of risk, with severe prolongations being associated with much higher risk. The most common etiology is acquired prolongation due to medication use, followed by electrolyte abnormalities. Less common are various conditions.&#x000a0;</p>
        <p>
<bold>Prolonged QT Etiologies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pharmacological</p>
          </list-item>
          <list-item>
            <p>Long QT syndrome</p>
          </list-item>
          <list-item>
            <p>Jervell and Lange-Neilson syndromes<xref ref-type="bibr" rid="article-43508.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Romano-Ward syndrome</p>
          </list-item>
          <list-item>
            <p>Hypocalcemia</p>
          </list-item>
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Hypomagnesemia</p>
          </list-item>
          <list-item>
            <p>Hypothyroidism</p>
          </list-item>
          <list-item>
            <p>Hypothermia</p>
          </list-item>
        </list>
        <p>Literature has shown that people with diabetes and those suffering from certain inflammatory diseases may suffer from mildly prolonged QT. This is also true in those with heart disease. No major evidence in the general population indicates changes in mortality are associated with mild QT prolongation. However, subsets of cardiac patients may have an increased mortality risk if they suffer from QT prolongation, especially when combined with other risk factors.<xref ref-type="bibr" rid="article-43508.r10">[10]</xref></p>
        <p>Pharmacological agents are the most common cause of QT prolongation, given the broad range of medications that may induce it.&#x000a0;Treatment is primarily aimed at&#x000a0;discontinuing the offending drug, as it usually leads to normalization of the QT interval.&#x000a0;</p>
        <p>
<bold>QT-Prolonging Medications</bold>
</p>
        <p><bold>Antipsychotics:</bold> Haloperidol, ziprasidone, quetiapine, thioridazine, olanzapine, risperidone, droperidol&#x000a0;</p>
        <p><bold>Antiarrhythmics:</bold> Amiodarone, sotalol, dofetilide,&#x000a0;procainamide, quinidine, flecainide</p>
        <p><bold>Antibiotics:</bold> Macrolides, fluoroquinolones</p>
        <p><bold>Antidepressants:</bold> Amitriptyline, imipramine, citalopram, amitriptyline</p>
        <p><bold>Others:</bold> Methadone, sumatriptan, ondansetron, cisapride</p>
        <p>A vast number of medications prolong the QT interval. They are preferably classified based on the degree of&#x000a0;QT prolongation they induce. This is specifically medication-dependent. Caution is advised&#x000a0;when combining QT-prolonging medications or when using these medications in those with electrolyte abnormalities, such as hypokalemia. Clinically, patients at risk of electrolyte derangements must also be considered. Specifically, those experiencing extrarenal losses and/or those on diuretics are at risk for electrolyte abnormalities and hence may have unknown prolonged QTc.&#x000a0;</p>
        <p>Many commonly used medications, such as diphenhydramine and azithromycin, exhibit QT-prolonging effects. However, the degree of&#x000a0;QT prolongation is not severe enough to warrant immediate caution in healthy patients. These medications bind to the&#x000a0;human ether-related gene (hERG) channels and reduce electrical conduction through the potassium ion channels. This results in delayed repolarization of the heart.<xref ref-type="bibr" rid="article-43508.r11">[11]</xref>&#x000a0;The actual risk of torsades de pointes remains unknown with these medications.&#x000a0;</p>
      </sec>
      <sec id="article-43508.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The&#x000a0;QT&#x000a0;interval is measured from the beginning of the QRS complex to the end&#x000a0;of the T wave. Mechanisms that prolong the action potential duration can prolong the QT interval. Specifically, this occurs by delaying the third phase of repolarization. When the hERG channels are&#x000a0;altered, there are changes made to the potassium ion channels. This causes an impairment of the channel's ability to conduct the electrical activity. The result is prolonged cardiac repolarization.</p>
        <p>This mechanism can occur via genetic changes to hERG and/or drug binding to these channels. Different drugs will induce changes in the hERG channels to variable degrees. Hence, different medications induce different levels of QT prolongation.<xref ref-type="bibr" rid="article-43508.r11">[11]</xref><xref ref-type="bibr" rid="article-43508.r12">[12]</xref><xref ref-type="bibr" rid="article-43508.r13">[13]</xref></p>
      </sec>
      <sec id="article-43508.s4" sec-type="Administration">
        <title>Administration</title>
        <p>QT-prolonging drugs can exist in various forms and be administered depending on the indication. This includes oral, rectal, intravenous, intramuscular, and other forms of administration. Any medication that is absorbed systemically can prolong the QT interval if they have QTc prolonging properties.&#x000a0;</p>
      </sec>
      <sec id="article-43508.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>QT prolongation increases the risk of torsades de pointes, a potentially lethal arrhythmia. Torsades de pointes&#x000a0;is a form of polymorphic ventricular tachycardia; it is initiated when a premature ventricular contraction occurs in the setting of a prolonged QT interval. This is known as the "R on T" phenomenon.<xref ref-type="bibr" rid="article-43508.r14">[14]</xref> It may cease on its own and return to sinus rhythm or degenerate into ventricular fibrillation. Not all polymorphic ventricular tachycardia is torsades de pointes, as this rhythm must occur in the setting of a prolonged QT interval.&#x000a0;</p>
        <p>The clinical feature of this arrhythmia&#x000a0;is often syncope. However, it can be asymptomatic. If it degenerates into ventricular fibrillation, death is the likely outcome if there is no intervention.<xref ref-type="bibr" rid="article-43508.r15">[15]</xref><xref ref-type="bibr" rid="article-43508.r16">[16]</xref><xref ref-type="bibr" rid="article-43508.r17">[17]</xref></p>
      </sec>
      <sec id="article-43508.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients diagnosed with long QT syndrome or any genetic causation of prolonged QT syndrome should use these medications with caution.&#x000a0;Patients with hypokalemia, hypomagnesemia, and&#x000a0;hypocalcemia&#x000a0;should be put on QT-prolonging medications with caution. Certain electrolyte derangements prolong QT, which these medications would further exacerbate.<xref ref-type="bibr" rid="article-43508.r18">[18]</xref>&#x000a0;Patients on diuretics or those experiencing symptoms such as diarrhea may have electrolyte abnormalities. Many of these patients may not have had electrolytes checked prior to being administered a QT-prolonging medication, and hence there must be cautious when prescribing these medications.&#x000a0;</p>
        <p>Medication interactions are another form of dangerous contraindication. Certain QT-prolonging medications are substrates of the cytochrome P450 (CYP450) system. If a patient is using a CYP450 inhibitor medication at the same time, there is a risk of significantly greater QT prolongation.</p>
      </sec>
      <sec id="article-43508.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients using medications that prolong the QT interval should ideally be monitored&#x000a0;with an ECG. Some medications induce minimal QT prolongation, and if there is no preexisting QT prolongation, then monitoring is unnecessary.&#x000a0;A normal QTc in men is 440 ms or less, and in women, it is 460 ms or less. It is ideal to have patients within those parameters when on a QT-prolonging medication. A longer QTc is tolerated&#x000a0;until it approaches or exceeds 500 ms.<xref ref-type="bibr" rid="article-43508.r19">[19]</xref></p>
        <p>The monitoring of electrolytes, specifically potassium, magnesium, and&#x000a0;calcium, should be done in patients with QT prolongation. The risk of further&#x000a0;QT&#x000a0;prolongation and torsades de&#x000a0;pointes&#x000a0;is increased when electrolyte abnormalities coexist with these medications.</p>
      </sec>
      <sec id="article-43508.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Prevention and treatment of QT prolongation require an interprofessional approach. Genetic causes require a specific diagnosis, which allows for avoiding aggravating factors. The usage of beta-blockers may lower the risk of torsades de pointes.&#x000a0;</p>
        <p>Pharmacological etiologies of QT prolongation are treated&#x000a0;by ceasing the offending medication. Any&#x000a0;coexisting electrolyte abnormalities should be treated. Optimization of potassium, magnesium, and calcium is essential to minimize the risk of torsades de pointes.<xref ref-type="bibr" rid="article-43508.r20">[20]</xref></p>
        <p>At the time of admission and discharge, the nurse should note all medications that affect the QT interval and notify the team. Cardiology nurses are responsible for monitoring patients, administering treatments, and reporting any change in clinical status to the clinician. Similarly, the pharmacist must keep track of the patient's medications and speak to the provider if any drugs can alter the QT interval. In most cases, medication-induced prolonged QT intervals can&#x000a0;be prevented&#x000a0;by an interprofessional, proactive approach. [Level 5]</p>
      </sec>
      <sec id="article-43508.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=43508&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=43508">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/43508/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=43508">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-43508.s10">
        <title>References</title>
        <ref id="article-43508.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Draghici</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The physiological basis and measurement of heart rate variability in humans.</article-title>
            <source>J Physiol Anthropol</source>
            <year>2016</year>
            <month>Sep</month>
            <day>28</day>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">27680542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gianni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burkhardt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Natale</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of the Purkinje network in premature ventricular complex-triggered ventricular fibrillation.</article-title>
            <source>J Interv Card Electrophysiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>375</fpage>
            <page-range>375-383</page-range>
            <pub-id pub-id-type="pmid">30066290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Postema</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The measurement of the QT interval.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-94</page-range>
            <pub-id pub-id-type="pmid">24827793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Al-Akchar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siddique</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <chapter-title>Long QT Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">28722890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Woosley</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval.</article-title>
            <source>Heart Rhythm</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>9</issue>
            <fpage>1003</fpage>
            <page-range>1003-7</page-range>
            <pub-id pub-id-type="pmid">16945790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Macfarlane</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs.</article-title>
            <source>J Electrocardiol</source>
            <year>2004</year>
            <volume>37 Suppl</volume>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">15534815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hazeki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yoshinaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Haraguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukushige</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagashima</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cut-offs for screening prolonged QT intervals from Fridericia's formula in children and adolescents.</article-title>
            <source>Circ J</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>8</issue>
            <fpage>1663</fpage>
            <page-range>1663-9</page-range>
            <pub-id pub-id-type="pmid">20534944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vandenberk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vandael</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robyns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Foulon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ector</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Willems</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Which QT Correction Formulae to Use for QT Monitoring?</article-title>
            <source>J Am Heart Assoc</source>
            <year>2016</year>
            <month>Jun</month>
            <day>17</day>
            <volume>5</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">27317349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ching</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Congenital long QT syndromes: clinical features, molecular genetics and genetic testing.</article-title>
            <source>Expert Rev Mol Diagn</source>
            <year>2006</year>
            <month>May</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-74</page-range>
            <pub-id pub-id-type="pmid">16706739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazzerini</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Capecchi</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Laghi-Pasini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls.</article-title>
            <source>Lupus Sci Med</source>
            <year>2016</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>e000189</fpage>
            <pub-id pub-id-type="pmid">28074146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Recanatini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poluzzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Masetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Ponti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.</article-title>
            <source>Med Res Rev</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-66</page-range>
            <pub-id pub-id-type="pmid">15389727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollard</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Abi Gerges</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bridgland-Taylor</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Easter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Valentin</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-21</page-range>
            <pub-id pub-id-type="pmid">20141516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saxena</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hortigon-Vinagre</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Beyl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baburin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Andranovits</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>IJzerman</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>K&#x000fc;gler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Timin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Hering</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Correlation between human ether-a-go-go-related gene channel inhibition and action potential prolongation.</article-title>
            <source>Br J Pharmacol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>174</volume>
            <issue>18</issue>
            <fpage>3081</fpage>
            <page-range>3081-3093</page-range>
            <pub-id pub-id-type="pmid">28681507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oksuz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sensoy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sahan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cetin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozeke</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Topaloglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The classical "R-on-T" phenomenon.</article-title>
            <source>Indian Heart J</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>392</fpage>
            <page-range>392-4</page-range>
            <pub-id pub-id-type="pmid">26304578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mourad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stiber</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Perfect</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>228</fpage>
            <page-range>228-233</page-range>
            <pub-id pub-id-type="pmid">30295798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmud</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nabeebaccus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Incidence and outcomes of long QTc in acute medical admissions.</article-title>
            <source>Int J Clin Pract</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>11</issue>
            <fpage>e13250</fpage>
            <pub-id pub-id-type="pmid">30222237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cumbler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pell</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reining in the QTc: reducing the risk of Torsades de Pointes across a major health system.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>1202</fpage>
            <page-range>1202-1205</page-range>
            <pub-id pub-id-type="pmid">29961858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golzari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Speroff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities.</article-title>
            <source>Conn Med</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>389</fpage>
            <page-range>389-97</page-range>
            <pub-id pub-id-type="pmid">17879860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravens</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Sex differences in cardiac electrophysiology.</article-title>
            <source>Can J Physiol Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>96</volume>
            <issue>10</issue>
            <fpage>985</fpage>
            <page-range>985-990</page-range>
            <pub-id pub-id-type="pmid">30001496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-43508.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment of acquired QT prolongation and torsades de pointes.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>420</fpage>
            <page-range>420-7</page-range>
            <pub-id pub-id-type="pmid">26183037</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
